公开(公告)号：US07737111B2

公开(公告)日：2010-06-15

申请号：US11272521

申请日：2005-11-10

申请人： Hosung Min ,  Hailing Hsu ,  Fei Xiong

发明人： Hosung Min ,  Hailing Hsu ,  Fei Xiong

IPC分类号： A61K38/10

CPC分类号： C07K7/08 ,  A61K38/00 ,  A61K38/10 ,  C07K1/047 ,  C07K14/001 ,  C07K14/4702 ,  C07K14/7151 ,  C07K16/241 ,  C07K2319/30 ,  C07K2319/74 ,  C12N15/1037 ,  C40B40/02

摘要： The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO:100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO:104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO:105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO:106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO:107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO:109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a—V1—(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

摘要翻译： 本发明涉及调节TALL-1活性的治疗剂。 根据本发明，TALL-1的调节剂可以包含氨基酸序列Dz2Lz4，其中z2是氨基酸残基，z4是苏氨酰基或异亮氨酰基。 示例性分子包括下式的一个序列（SEQ。ID NO：100）a1a2a3CDa6La8a9a10Ca12a13a14，（SEQ ID NO：104）b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18（SEQ ID。NO：105）c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18（SEQ ID。NO：106）d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18（ SEQ ID NO：107）e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18（SEQ ID NO：109）f1f2f3Kf5Df7Lf9f10Qf12f13f14其中取代基如说明书中所定义。 本发明还包括式（X1）a-V1-（X2）b的物质的组合物，其中V1是共价连接到一种或多种上述TALL-1调节组合物的载体。 载体和TALL-1调节组合物可以通过TALL-1调节部分的N末端或C末端连接。 优选的载体是Fc结构域，优选的Fc结构域是IgG Fc结构域。

公开(公告)号：US20060135431A1

公开(公告)日：2006-06-22

申请号：US11272521

申请日：2005-11-10

申请人： Hosung Min ,  Hailing Hsu ,  Fei Xiong

发明人： Hosung Min ,  Hailing Hsu ,  Fei Xiong

IPC分类号： A61K38/10 ,  C07K7/08

CPC分类号： C07K7/08 ,  A61K38/00 ,  A61K38/10 ,  C07K1/047 ,  C07K14/001 ,  C07K14/4702 ,  C07K14/7151 ,  C07K16/241 ,  C07K2319/30 ,  C07K2319/74 ,  C12N15/1037 ,  C40B40/02

摘要： The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO:100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO:104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO:105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO:106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO:107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO:109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a-V1-(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

公开(公告)号：US20100240590A1

公开(公告)日：2010-09-23

申请号：US12788137

申请日：2010-05-26

申请人： Hosung MIN ,  Hailing Hsu ,  Fei Xiong

发明人： Hosung MIN ,  Hailing Hsu ,  Fei Xiong

IPC分类号： A61K38/19 ,  A61P37/00 ,  A61P35/00

CPC分类号： C07K7/08 ,  A61K38/00 ,  A61K38/10 ,  C07K1/047 ,  C07K14/001 ,  C07K14/4702 ,  C07K14/7151 ,  C07K16/241 ,  C07K2319/30 ,  C07K2319/74 ,  C12N15/1037 ,  C40B40/02

摘要： The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a-V1-(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

摘要翻译： 本发明涉及调节TALL-1活性的治疗剂。 根据本发明，TALL-1的调节剂可以包含氨基酸序列Dz2Lz4，其中z2是氨基酸残基，z4是苏氨酰基或异亮氨酰基。 示例性分子包括下式的一个序列（SEQ。ID NO：100）a1a2a3CDa6La8a9a10Ca12a13a14，（SEQ ID NO：104）b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18（SEQ ID。NO：105）c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18（SEQ ID。NO：106）d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18（ SEQ ID NO：107）e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18（SEQ ID NO：109）f1f2f3Kf5Df7Lf9f10Qf12f13f14其中取代基如说明书中所定义。 本发明还包括式（X1）a-V1-（X2）b的物质的组合物，其中V1是共价连接到一种或多种上述TALL-1调节组合物的载体。 载体和TALL-1调节组合物可以通过TALL-1调节部分的N末端或C末端连接。 优选的载体是Fc结构域，优选的Fc结构域是IgG Fc结构域。

公开(公告)号：US08507426B2

公开(公告)日：2013-08-13

申请号：US12788137

申请日：2010-05-26

申请人： Hosung Min ,  Hailing Hsu ,  Fei Xiong

发明人： Hosung Min ,  Hailing Hsu ,  Fei Xiong

IPC分类号： A61K38/10

CPC分类号： C07K7/08 ,  A61K38/00 ,  A61K38/10 ,  C07K1/047 ,  C07K14/001 ,  C07K14/4702 ,  C07K14/7151 ,  C07K16/241 ,  C07K2319/30 ,  C07K2319/74 ,  C12N15/1037 ,  C40B40/02

摘要： The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ ID NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ ID NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ ID NO: 105) c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18 (SEQ ID NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ ID NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a-V1-(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

摘要翻译： 本发明涉及调节TALL-1活性的治疗剂。 根据本发明，TALL-1的调节剂可以包含氨基酸序列Dz2Lz4，其中z2是氨基酸残基，z4是苏氨酰基或异亮氨酰基。 示例性分子包括下式的一个序列（SEQ ID NO：100）a1a2a3CDa6La8a9a10Ca12a13a14，（SEQ ID NO：104）b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18（SEQIDNO：105）c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18（SEQIDNO：106）d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18（SEQIDNO：107）e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18（SEQIDNO：109）f1f2f3Kf5Df7Lf9f10Qf12f13f14其中所述取代基如 在规范中定义。 本发明还包括式（X1）a-V1-（X2）b的物质的组合物，其中V1是共价连接到一种或多种上述TALL-1调节组合物的载体。 载体和TALL-1调节组合物可以通过TALL-1调节部分的N末端或C末端连接。 优选的载体是Fc结构域，优选的Fc结构域是IgG Fc结构域。

公开(公告)号：US07259137B2

公开(公告)日：2007-08-21

申请号：US10145206

申请日：2002-05-13

申请人： Hosung Min ,  Hailing Hsu ,  Fei Xiong

发明人： Hosung Min ,  Hailing Hsu ,  Fei Xiong

IPC分类号： C07K7/00 ,  C07K14/00

CPC分类号： C07K7/08 ,  A61K38/00 ,  A61K38/10 ,  C07K1/047 ,  C07K14/001 ,  C07K14/4702 ,  C07K14/7151 ,  C07K16/241 ,  C07K2319/30 ,  C07K2319/74 ,  C12N15/1037 ,  C40B40/02

摘要： The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a-V1-(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

公开(公告)号：US20130044521A1

公开(公告)日：2013-02-21

申请号：US13586096

申请日：2012-08-15

申请人： Qiming Zhao ,  Fei Xiong ,  Jianyu Xie ,  Xue Jiang ,  Yimin Liang

发明人： Qiming Zhao ,  Fei Xiong ,  Jianyu Xie ,  Xue Jiang ,  Yimin Liang

IPC分类号： H02M3/335

CPC分类号： H02M3/335 ,  H02M1/425 ,  H05B33/0815 ,  Y02B70/126

摘要： A switching power supply comprising a switching circuit and a controller. The controller comprises a preprocessing circuit, a first multiplier, a first comparing circuit and a logic circuit. The controller comprises a preprocessing circuit, a first multiplier, a first comparing circuit and a logic circuit. The preprocessing circuit generates a first multiplication input signal based on the input voltage and output voltage of the switching circuit. The first multiplier multiplies the first multiplication input signal by a second multiplication input signal and generates a first product signal. The first comparing circuit compares a current sensing signal representative of the input current with the first product signal and generates a first comparison signal. The logic circuit turns off a main switch in the switching circuit when the current sensing signal is larger than the first product signal.

摘要翻译： 一种开关电源，包括开关电路和控制器。 控制器包括预处理电路，第一乘法器，第一比较电路和逻辑电路。 控制器包括预处理电路，第一乘法器，第一比较电路和逻辑电路。 预处理电路基于开关电路的输入电压和输出电压生成第一乘法输入信号。 第一乘法器将第一乘法输入信号乘以第二乘法输入信号并产生第一乘积信号。 第一比较电路将表示输入电流的电流感测信号与第一乘积信号进行比较，并产生第一比较信号。 当电流感测信号大于第一产品信号时，逻辑电路关断开关电路中的主开关。

公开(公告)号：US20130044123A1

公开(公告)日：2013-02-21

申请号：US13210381

申请日：2011-08-16

申请人： Harshit Shah ,  Erik Daniel Anderson ,  Veljko Miljanic ,  Fei Xiong ,  Paul Stephen Gildea ,  Kevin Welton ,  Markus Mielke ,  Sebastian Poulose

发明人： Harshit Shah ,  Erik Daniel Anderson ,  Veljko Miljanic ,  Fei Xiong ,  Paul Stephen Gildea ,  Kevin Welton ,  Markus Mielke ,  Sebastian Poulose

IPC分类号： G06T11/40

CPC分类号： G06F8/38 ,  G06T11/001

摘要： Techniques involving dynamic colorization of graphical user interfaces. One representative technique includes enabling a user to specify colors in which user interface elements will be colored in an application. An application colorization service is initiated in response to the user specification of the colors, which is used at least to obtain the colors specified by the user, and to create bitmap images of the application's user interface elements using the user-specified colors. A bitmap image output location is made accessible to the application to enable the application to retrieve the created bitmap images, and present the application using the application user interface elements having the user-specified colors.

摘要翻译： 涉及图形用户界面动态着色的技术。 一种代表性的技术包括使用户能够指定用户界面元素将在应用中被着色的颜色。 响应于颜色的用户指定启动应用程序着色服务，该颜色至少用于获得用户指定的颜色，并且使用用户指定的颜色来创建应用程序的用户界面元素的位图图像。 应用程序使位图图像输出位置可访问，以使应用程序能够检索创建的位图图像，并使用具有用户指定颜色的应用程序用户界面元素呈现应用程序。

公开(公告)号：US08008453B2

公开(公告)日：2011-08-30

申请号：US11502761

申请日：2006-08-10

申请人： Colin V. Gegg ,  Kenneth W. Walker ,  Leslie P. Miranda ,  Fei Xiong

发明人： Colin V. Gegg ,  Kenneth W. Walker ,  Leslie P. Miranda ,  Fei Xiong

IPC分类号： C07K16/00 ,  A61K38/00

CPC分类号： A61K47/48369 ,  A61K38/02 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6817 ,  C07K16/00 ,  C07K17/00 ,  C07K2317/40 ,  C07K2317/52

摘要： Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

摘要翻译： 公开了制备药理活性化合物的方法，其中选择Fc结构域序列的至少一个内部缀合位点，其适于通过定义的缀合化学通过氨基酸残基的侧链与另外的功能部分缀合 在共轭位点。 用于缀合的合适的氨基酸残基可以在缀合位点处的天然Fc结构域中存在，或者可以通过插入（即天然Fc结构域中的氨基酸之间）或替换（即，除去氨基酸并用不同的氨基 酸）。 在后一种情况下，加入的氨基酸数不需要对应于从先前存在的Fc结构域去除的氨基酸的数目。 该技术可用于生产含有它们的物质和药物组合物的有用组合物。 还公开了编码本发明组合物的DNA，含有该DNA的表达载体和含有表达载体的宿主细胞。

公开(公告)号：US07750128B2

公开(公告)日：2010-07-06

申请号：US12221417

申请日：2008-08-01

申请人： Colin Gegg ,  Fei Xiong ,  Karen C. Sitney

发明人： Colin Gegg ,  Fei Xiong ,  Karen C. Sitney

IPC分类号： C07K16/00 ,  A61K38/00

CPC分类号： C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2318/10 ,  C07K2319/30

摘要： The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.

公开(公告)号：US07662931B2

公开(公告)日：2010-02-16

申请号：US12221418

申请日：2008-08-01

申请人： Colin Gegg ,  Fei Xiong ,  Karen C. Sitney

发明人： Colin Gegg ,  Fei Xiong ,  Karen C. Sitney

IPC分类号： C07K16/00 ,  A61K38/00

CPC分类号： C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2318/10 ,  C07K2319/30

摘要： The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.